Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy

Trials

Volumn 8, Issue , 2007, Pages

  Hirsh, Vera ^a   Glaspy, John ^b   Mainwaring, Paul ^c   Manegold, Christian ^d   Ramlau, Rodryg ^e   Eid, Joseph E ^f  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MATER ADULT HOSPITAL   (Australia)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Regional Hospital for Lung Diseases   (Poland)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; DIGOXIN; GEFITINIB; GEMCITABINE; HEMOGLOBIN; IRON; TAXANE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; ATRIOVENTRICULAR BLOCK; BACKACHE; BLOOD TRANSFUSION; BONE PAIN; BRAIN METASTASIS; CANCER GROWTH; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLUSHING; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOGLOBIN DETERMINATION; HEMOPTYSIS; HUMAN; HYPERTENSION; INJECTION SITE DISCOMFORT; INJECTION SITE PAIN; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OPTIMAL DRUG DOSE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT DURATION;

EID: 33947585511     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-8-8     Document Type: Article

References (49)

1. Jemal A Murray T Ward E Samuels A Tiwari RC Ghafoor A Feuer EJ Thun MJ Cancer statistics, 2005 CA Cancer J Clin 2005 55 1 10-30 15661684
2. Groopman JE Itri LM Chemotherapy-induced anemia in adults: Incidence and treatment J Natl Cancer Inst 1999 91 19 1616-1634 10.1093/jnci/ 91.19.1616 10511589
3. Kelly K Crowley J Bunn PA Jr Presant CA Grevstad PK Moinpour CM Ramsey SD Wozniak AJ Weiss GR Moore DF Israel VK Livingston RB Gandara DR Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial J Clin Oncol 2001 19 13 3210-3218 11432888
4. Sweeney CJ Zhu J Sandler AB Schiller J Belani CP Langer C Krook J Harrington D Johnson DH Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A Phase II trial in patients with metastatic nonsmall cell lung carcinoma Cancer 2001 92 10 2639-2647 10.1002/ 1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8 11745199
5. Kosmidis P Krzakowski M The ECAS Investigators Anemia profiles in patients with lung cancer: What have we learned from the European Cancer Anaemia Survey (ECAS)? Lung Cancer 2005 50 3 401-412 10.1016/ j.lungcan.2005.08.004 16191450
6. Crawford J Anemia and lung cancer Lung Cancer 2002 38 Suppl 3 S75-S78 10.1016/S0169-5002(02)00275-1 12468152
7. Langer CJ Choy H Glaspy JA Colowick A Standards of care for anemia management in oncology: Focus on lung carcinoma Cancer 2002 95 3 613-623 10.1002/cncr.10712 12209755
8. Nowrousian MR Kasper C Oberhoff C Essers U Voigtmann R Gallasch W Quarder O Pathophysiology of cancer-related anemia rhErythropoietin in Cancer Supportive Treatment New York: Marcel Dekker, Inc Smyth JF, Boogaerts MA, Ehmer BR-M 1996 13-34
9. Faquin WC Schneider TJ Goldberg MA Effect of inflammatory cytokines on hypoxia-induced erythropoietin production Blood 1992 79 8 1987-1994 1373333
10. Cella D Factors influencing quality of life in cancer patients: Anemia and fatigue Semin Oncol 1998 25 3 Suppl 7 43-46 9671330
11. Pirker R Wiesenberger K Pohl G Minar W Anemia in lung cancer: Clinical impact and management Clin Lung Cancer 2003 5 2 90-97 14596691
12. Morère JF Role of epoetin in the management of anaemia in patients with lung cancer Lung Cancer 2004 46 2 149-156 10.1016/ j.lungcan.2004.04.034 15474662
13. Albain KS Crowley JJ LeBlanc M Livingston RB Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience J Clin Oncol 1991 9 9 1618-1626 1651993
14. MacRae R Shyr Y Johnson D Choy H Declining hemoglobin during chemoradiotherapy for locally advanced non-small cell lung cancer is significant Radiother Oncol 2002 64 1 37-40 10.1016/ S0167-8140(02)00151-2 12208573
15. Robnett TJ Machtay M Hahn SM Shrager JB Friedberg JS Kaiser LR Pathological response to preoperative chemoradiation worsens with anemia in non-small cell lung cancer patients Cancer J 2002 8 3 263-267 12074326
16. Barrett-Lee PJ Bailey NP O'Brien ME Wager E Large scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy Br J Cancer 2000 82 1 93-97 10.1054/ bjoc.1999.0883 10638973
17. Goodnough LT Brecher ME Kanter MH AuBuchon JP Transfusion medicine. First of two parts - blood transfusion N Engl J Med 1999 340 6 438-447 10.1056/NEJM199902113400606 9971869
18. Littlewood TJ Bajetta E Nortier JW Vercammen E Rapoport B Epoetin Alfa Study Group Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial J Clin Oncol 2001 19 11 2865-2874 11387359
19. Österborg A Brandberg Y Molostova V Iosava G Abdulkadyrov K Hedenus M Messinger D Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies J Clin Oncol 2002 20 10 2486-2494 10.1200/JCO.2002.08.131 12011126
20. Vansteenkiste J Pirker R Massuti B Barata F Font A Fiegl M Siena S Gateley J Tomita D Colowick AB Musil J Aranesp 980297 Study Group Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 2002 94 16 1211-1220 12189224
21. Boogaerts M Coiffier B Kainz C Epoetin β QOL Working Group Impact of epoetin β on quality of life in patients with malignant disease Br J Cancer 2003 88 7 988-995 10.1038/sj.bjc.6600801 12671693
22. Wilkinson PM Antonopoulos M Lahousen M Lind M Kosmidis P EPO-INT-45 Study Group Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial Br J Cancer 2006 94 7 947-954 10.1038/sj.bjc.6603004 16570051
23. Cazzola M Beguin Y Kloczko J Spicka I Coiffier B Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production Br J Haematol 2003 122 3 386-393 10.1046/ j.1365-2141.2003.04439.x 12877665
24. Waltzman R Croot C Justice GR Fesen MR Charu V Williams D Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy Oncologist 2005 10 8 642-650 10.1634/theoncologist.10-8-642 16177289
25. Macdougall IC Bailon P Tare T Pahlke W CERA (Continuous Erythropoiesis Receptor Activator) for the treatment of renal anemia: An innovative agent with unique receptor binding characteristics and prolonged serum half-life J Am Soc Nephrol 2003 14 769A (Abstract SU-PO1063)
26. Macdougall IC CERA (Continuous Erythropoietin Receptor Activator): A new erythropoiesis-stimulating agent for the treatment of anemia Curr Hematol Rep 2005 4 6 436-440 16232379
27. Dmoszynska A Klockzo J Rokicka M Hellmann A Spicka I Efficacy and pharmacokinetics of CERA (Continuous Erythropoiesis Receptor Activator) in patients with multiple myeloma: An exploratory Phase I-II dose escalation study Proc Am Soc Clin Oncol 2004 23 568 (Abstract 6552)
28. Haselbeck A Reigner B Jordan P Pannier A Glaspy J Pre-clinical and Phase I pharmacokinetic and mode-of-action studies of CERA (Continuous Erythropoiesis Receptor Activator), an innovative erythropoietic agent with an extended serum half-life Proc Am Soc Clin Oncol 2003 22 748 (Abstract 3006)
29. Dougherty FC Reigner B Jordan P Pannier A Continuous Erythropoiesis Receptor Activator (CERA) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers Ann Oncol 2004 15 Suppl 3 iii157 (Abstract 592)
30. Reigner B Jordan P Pannier A Glaspy J CERA (Continuous Erythropoiesis Receptor Activator), an innovative agent: Dose-dependent response in Phase I studies Proc Am Soc Clin Oncol 2003 22 732 (Abstract 2943)
31. Hedenus M Adriansson M San Miguel J Kramer MH Schipperus MR Juvonen E Taylor K Belch A Altes A Martinelli G Watson D Matcham J Rossi G Littlewood TJ Darbepoetin Alfa 20000161 Study Group Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study Br J Haematol 2003 122 3 394-403 10.1046/j.1365-2141.2003.04448.x 12877666
32. Henry DH Brooks BJ Jr Case DC Jr Fishkin E Jacobson R Keller AM Kugler J Moore J Silver RT Storniolo AM Abels RI Gordon DS Nelson R Larholt K Bryant E Rudnick S Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy Cancer J Sci Am 1995 1 4 252-260 9166485
33. Thatcher N De Campos ES Bell DR Steward WP Varghese G Morant R Vansteenkiste JF Rosso R Ewers SB Sundal E Schatzmann E Stocker H Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer Br J Cancer 1999 80 3-4 396-402 10.1038/sj.bjc.6690369 10408844
34. Crawford J Demetri GD Gabrilove JL Blasi MV Sarokhan BJ Glaspy J Clinical benefits of epoetin alfa therapy in patients with lung cancer Clin Lung Cancer 2002 3 3 180-190 14662041
35. Casas F Vinolas N Ferrer F Farrus B Gimferrer JM Agusti C Belda J Luburich P Improvement in performance status after erythropoietin treatment in lung cancer patients undergoing concurrent chemoradiotherapy Int J Radiat Oncol Biol Phys 2003 55 1 116-124 10.1016/ S0360-3016(02)03823-3 12504043
36. Schwartzberg LS Yee LK Senecal FM Charu V Tomita D Wallace J Rossi G A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer Oncologist 2004 9 6 696-707 10.1634/theoncologist.9-6-696 15561813
37. Coiffier B Epoetin once weekly in anaemic patients with cancer Br J Haematol 2004 125 1 100-101 10.1111/j.1365-2141.2004.04887.x 15015984
38. Hardut D Wiesenberger K Minar W Pirker R Epoetin beta in patients with lung cancer receiving chemotherapy Lung Cancer 2003 41 Suppl 2 S264 (Abstract AP-6821) 10.1016/S0169-5002(03)92649-3
39. Ariganello O Mancuso A Di Molfetta M Diana F Beccaglia P Cortesi E De Marinis F A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer Lung Cancer 2004 46 1 119-124 10.1016/ j.lungcan.2004.03.017 15364140
40. Pirker R Lehnert M Minar W Epoetin beta 30,000 IU once weekly for the treatment of anaemia in patients with lung cancer receiving chemotherapy: A prospective survey of the efficacy and timing of treatment in a clinical setting Lung Cancer 2005 49 Suppl 2 S340 (Abstract P-840) 10.1016/S0169-5002(05)81333-9
41. Cheung WK Danneman B Wacholtz M Lau H Miller D Pharmacokinetics (PK) and pharmacodynamics (PD) of epoetin alfa in anemic cancer patients receiving cycling chemotherapy Blood 2004 104 11 (Abstract 4101)
42. Procrit® (epoetin alfa) package insert Ortho Biotech Products, LP Raritan NJ 2004
43. Halstenson CE Macres M Katz SA Schnieders JR Watanabe M Sobota JT Abraham PA Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta Clin Pharmacol Ther 1991 50 6 702-712 1752115
44. Glaspy J Henry D Patel R Tchekmedyian S Applebaum S Berdeaux D Lloyd R Berg R Austin M Rossi G Darbepoetin Alfa 20010162 Study Group Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: A randomized clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa Eur J Cancer 2005 41 8 1140 -1149 10.1016/ j.ejca.2005.01.021 15911237
45. Heatherington AC Dittrich C Sullivan JT Rossi G Schueller J Pharmacokinetics of darbepoetin alfa after intravenous or subcutaneous administration in patients with non-myeloid malignancies undergoing chemotherapy Clin Pharmacokinet 2006 45 2 199-211 10.2165/ 00003088-200645020-00005 16485917
46. Macdougall IC Gray SJ Elston O Breen C Jenkins B Browne J Egrie J Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients J Am Soc Nephrol 1999 10 11 2392-2395 10541299
47. Macdougall IC Robson R Opatrna S Liogier X Pannier A Reigner B Dougherty FC Pharmacologic profile of CERA (Continuous Erythropoietin Receptor Activator) in chronic kidney disease (CKD) patients (pts) following intravenous (IV) and subcutaneous (SC) administration J Am Soc Nephrol 2005 16 759A (Abstract SA-PO926)
48. Bohlius J Langensiepen S Schwarzer G Seidenfeld J Piper M Bennett C Engert A Recombinant human erythropoietin and overall survival in cancer patients: Results of a comprehensive meta-analysis J Natl Cancer Inst 2005 97 16 489-498 15812074
49. Coiffier B Boogaerts M Aapro M Huber M Burger H-U Thromboembolic events in patients with cancer treated with epoetin beta: A meta-analysis of controlled clinical trials Ann Oncol 2004 3 iii221 (Abstract 840P)